Menu

ISTOCK, HENRIK5000

Ebola Update: More Experimental Treatments, Health Workers at Risk

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

Aug 23, 2018
Catherine Offord

Health workers in Democratic Republic of Congo have begun giving patients two experimental treatments to tackle the latest outbreak of Ebola as the number of cases climbs above 100, Reuters reports. The first dose of Gilead Science’s antiviral drug Remdesivir was administered on Tuesday (August 21), while the monoclonal antibody treatment mAb114 was deployed nearly two weeks ago. 

“As of 20 August 2018, a total of 102 confirmed and probable [Ebola virus disease] cases, including 59 deaths, have been reported,” the World Health Organization (WHO) writes in a situation report published yesterday (August 22). Besides mAb114, “The Ethics Committee in the Democratic Republic of the Congo has approved the use of four additional experimental therapeutics, namely: ZMapp, Remdesivir, Favipiravir, and Regn3450 - 3471 – 3479” to be used by Ebola treatment centers.

See “Q&A: Anthony Fauci Describes an Experimental Ebola Treatment

The latest outbreak was discovered at the beginning of August near Beni, a city in the eastern part of the country that is currently experiencing militia violence—an obstacle to the work of health authorities trying to contain the virus. “We don’t know if we are having all transmission chains identified,” WHO spokesman Tarik Jasarevic said during a news briefing in Geneva, Reuters reported last week (August 17). “The worst-case scenario is that we have these security blindspots where the epidemic could take hold that we don’t know about.”

See “New Ebola Outbreak in Democratic Republic of Congo

Health workers have been particularly affected by the latest outbreak, accounting for 12 of the 75 cases that have been confirmed so far. “There’s an extremely low level of knowledge and awareness about Ebola in the area,” epidemiologist Peter Salama, head of the WHO’s response to the outbreak, tells Science. “Early on, the health care workers took no precautions whatsoever, and unfortunately, we’re expecting more confirmed cases from that group.”

Meanwhile, vaccination teams are continuing to administer an experimental Ebola vaccine, Merck’s rVSV-ZEBOV, to health workers and people in contact with Ebola patients. Reuters reports that 2,179 people have received the vaccine so far, and more doses are on their way to Beni now.

See “Experimental Ebola Vaccinations to Resume in Democratic Republic of Congo

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing